Cargando…

Report of a TREAT-NMD/World Duchenne Organisation Meeting on Dystrophin Quantification Methodology

Representatives of academia, patient organisations, industry and the United States Food and Drug Administration attended a workshop on dystrophin quantification methodology. The aims of the workshop were to provide an overview of methods used to quantify dystrophin levels in human skeletal muscle an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Aartsma-Rus, Annemieke, Morgan, Jennifer, Lonkar, Pallavi, Neubert, Hendrik, Owens, Jane, Binks, Michael, Montolio, Marisol, Phadke, Rahul, Datson, Nicole, Van Deutekom, Judith, Morris, Glenn E., Rao, V. Ashutosh, Hoffman, Eric P., Muntoni, Francesco, Arechavala-Gomeza, Virginia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	IOS Press 2019
Materias:	Meeting Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6398559/ https://www.ncbi.nlm.nih.gov/pubmed/30614809 http://dx.doi.org/10.3233/JND-180357

Ejemplares similares

Splicing modulation therapy in the treatment of genetic diseases
por: Arechavala-Gomeza, Virginia, et al.
Publicado: (2014)

Good news for the mdx mouse community: Improved dystrophin restoration after skipping mouse dystrophin exon 23
por: Aartsma-Rus, Annemieke
Publicado: (2022)

Dystrophin and mini-dystrophin quantification by mass spectrometry in skeletal muscle for gene therapy development in Duchenne muscular dystrophy
por: Farrokhi, Vahid, et al.
Publicado: (2021)

A multicenter comparison of quantification methods for antisense oligonucleotide-induced DMD exon 51 skipping in Duchenne muscular dystrophy cell cultures
por: Hiller, Monika, et al.
Publicado: (2018)

Influence of full-length dystrophin on brain volumes in mouse models of Duchenne muscular dystrophy
por: Kogelman, Bauke, et al.
Publicado: (2018)

Dual exon skipping in myostatin and dystrophin for Duchenne muscular dystrophy
por: Kemaladewi, Dwi U, et al.
Publicado: (2011)

Antisense-induced exon skipping for duplications in Duchenne muscular dystrophy
por: Aartsma-Rus, Annemieke, et al.
Publicado: (2007)

Circulating Biomarkers for Duchenne Muscular Dystrophy
por: Aartsma-Rus, Annemieke, et al.
Publicado: (2015)

A Duchenne Muscular Dystrophy Gene Hot Spot Mutation in Dystrophin-Deficient Cavalier King Charles Spaniels Is Amenable to Exon 51 Skipping
por: Walmsley, Gemma L., et al.
Publicado: (2010)

Use of capillary Western immunoassay (Wes) for quantification of dystrophin levels in skeletal muscle of healthy controls and individuals with Becker and Duchenne muscular dystrophy
por: Beekman, Chantal, et al.
Publicado: (2018)

Multiomic characterization of disease progression in mice lacking dystrophin
por: Signorelli, Mirko, et al.
Publicado: (2023)

Low human dystrophin levels prevent cardiac electrophysiological and structural remodelling in a Duchenne mouse model
por: Marchal, Gerard A., et al.
Publicado: (2021)

Assessment of the feasibility of exon 45–55 multiexon skipping for duchenne muscular dystrophy
por: van Vliet, Laura, et al.
Publicado: (2008)

The importance of genetic diagnosis for Duchenne muscular dystrophy
por: Aartsma-Rus, Annemieke, et al.
Publicado: (2016)

Autophagy is Impaired in the Tibialis Anterior of Dystrophin Null Mice
por: Spitali, Pietro, et al.
Publicado: (2013)

FDA Approves Eteplirsen for Duchenne Muscular Dystrophy: The Next Chapter in the Eteplirsen Saga
por: Aartsma-Rus, Annemieke, et al.
Publicado: (2017)

Imperatives for DUCHENNE MD: a Simplified Guide to Comprehensive Care for Duchenne Muscular Dystrophy
por: Kinnett, Kathi, et al.
Publicado: (2015)

Timing and localization of human dystrophin isoform expression provide insights into the cognitive phenotype of Duchenne muscular dystrophy
por: Doorenweerd, Nathalie, et al.
Publicado: (2017)

The Effect of 6-Thioguanine on Alternative Splicing and Antisense-Mediated Exon Skipping Treatment for Duchenne Muscular Dystrophy
por: Verhaart, Ingrid E. C., et al.
Publicado: (2012)

Author Correction: Timing and localization of human dystrophin isoform expression provide insights into the cognitive phenotype of Duchenne muscular dystrophy
por: Doorenweerd, Nathalie, et al.
Publicado: (2018)

Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study
por: Cirak, Sebahattin, et al.
Publicado: (2011)

miR-106b is a novel target to promote muscle regeneration and restore satellite stem cell function in injured Duchenne dystrophic muscle
por: Rodriguez-Outeiriño, Lara, et al.
Publicado: (2022)

Non-sequential and multi-step splicing of the dystrophin transcript
por: Gazzoli, Isabella, et al.
Publicado: (2015)

Increased dystrophin production with golodirsen in patients with Duchenne muscular dystrophy
por: Frank, Diane E., et al.
Publicado: (2020)

Dystrophin quantification: Biological and translational research implications
por: Anthony, Karen, et al.
Publicado: (2014)

Startle responses in Duchenne muscular dystrophy: a novel biomarker of brain dystrophin deficiency
por: Maresh, Kate, et al.
Publicado: (2022)

Improving translatability of preclinical studies for neuromuscular disorders: lessons from the TREAT-NMD Advisory Committee for Therapeutics (TACT)
por: Willmann, Raffaella, et al.
Publicado: (2020)

The TREAT-NMD DMD Global Database: Analysis of More than 7,000 Duchenne Muscular Dystrophy Mutations
por: Bladen, Catherine L, et al.
Publicado: (2015)

Generation of Embryonic Stem Cells and Mice for Duchenne Research
por: Veltrop, Marcel, et al.
Publicado: (2013)

Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study
por: Kinali, Maria, et al.
Publicado: (2009)

A novel high-throughput immunofluorescence analysis method for quantifying dystrophin intensity in entire transverse sections of Duchenne muscular dystrophy muscle biopsy samples
por: Sardone, Valentina, et al.
Publicado: (2018)

CRISPR applications for Duchenne muscular dystrophy: From animal models to potential therapies
por: Chey, Yu C. J., et al.
Publicado: (2022)

Assessment of Behavioral Characteristics With Procedures of Minimal Human Interference in the mdx Mouse Model for Duchenne Muscular Dystrophy
por: Engelbeen, Sarah, et al.
Publicado: (2021)

Development of Exon Skipping Therapies for Duchenne Muscular Dystrophy: A Critical Review and a Perspective on the Outstanding Issues
por: Aartsma-Rus, Annemieke, et al.
Publicado: (2017)

Utrophin modulator drugs as potential therapies for Duchenne and Becker muscular dystrophies
por: Soblechero‐Martín, Patricia, et al.
Publicado: (2021)

Next Generation Exon 51 Skipping Antisense Oligonucleotides for Duchenne Muscular Dystrophy
por: van Deutekom, Judith, et al.
Publicado: (2023)

Affinity proteomics within rare diseases: a BIO-NMD study for blood biomarkers of muscular dystrophies
por: Ayoglu, Burcu, et al.
Publicado: (2014)

Case Report: The Genetic Diagnosis of Duchenne Muscular Dystrophy in the Middle East
por: Alghamdi, Fouad, et al.
Publicado: (2021)

Investigating the role of dystrophin isoform deficiency in motor function in Duchenne muscular dystrophy
por: Chesshyre, Mary, et al.
Publicado: (2022)

Digital Droplet PCR for the Absolute Quantification of Exon Skipping Induced by Antisense Oligonucleotides in (Pre-)Clinical Development for Duchenne Muscular Dystrophy
por: Verheul, Ruurd C., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_5jsptq1rukiqfo3apov96olt9k